Norway for life science

/in , , , , , , /by

The Norway for life science stand at NLS days 2019.

The biggest key players from the life science industry in Norway came together in Malmö with a common goal: to promote Norwegian life science and build Nordic collaboration.

The life science industry in Norway is booming and collaboration across Nordic borders is of increasing importance. That is why Oslo Cancer Cluster arranged the stand “Norway for Life Science” this year at the Nordic Life Science Days in Malmö.

Among the participants of the stand were governmental institutions, cluster organisations, private companies and academic institutions.

 

Promoting collaboration

On Wednesday, a delegation from the Norwegian Embassy in Sweden attended for an informal meet and greet with the Norwegian life science milieu. This was an excellent opportunity to share knowledge about Nordic cooperation and to strengthen joint activities within the life sciences.

See the video with Kirsten Hammelbo, Minister / Deputy Head of Mission, Norwegian Embassy below.

 

Standing together

The participants of the stand were altogether positive about the initiative and agreed it was a constructive platform to build new relationships. We asked some of the participants the same question: Why is it important for you to be here at NLS days?

“Our main focus here at NLS Days is Nordic collaboration, both public and private, to promote the life science industry.”
Catherine Capdeville, Senior Adviser, Innovation Norway

“It is important to follow what is happening in the industry and in other innovation environments. We are here to nurture our existing contacts and find new partners.”
Morten Egeberg, Administrative leader, UiO Life Science

“Firstly, it is important to show that Norway stands together. This is a significant meeting place. We consider the Nordic countries to be our home market, so we try to present what we do here. It is important for one actor to take responsibility, like Oslo Cancer Cluster does, so that we can collectively gather here.”
Anita Moe Larsen, Head of Communication, Norway Health Tech

“In the long term, we have research projects where we are looking for contacts in the life science industry – both partners of collaboration and potential clients. We are here to promote the centre and let everyone know that we exist.”
Alexandra Patriksson, Senior Adviser, Centre for Digital Life

“We are here to strengthen our collaboration with the best research environments in neuroscience. We want to show that the health industry in Norway is growing and what we can do when we stand together.”
Bjarte Reve, CEO, Nansen Neuroscience Network

“We are happy to contribute to make Norwegian life sciences visible and to show what Norway can offer as a host country, and attract potential investors and collaborating partners in research and innovation. And especially to make visible and be a part of the Norwegian community in this field. It is unusual in Norway that so many different players, both public and private, stand together in one stand – with one common goal.”
Espen Snipstad, Communications Manager, LMI

 

Full list of partners:

 

Sign up to OCC monthly newsletter

Geir Harstad, CEO of Smartfish, is encouraged by clinical study results indicating that the company's medical nutrition has the potential to enhance the efficacy of standard cancer treatments. Photo: Smartfish

Smartfish with clinical study results

/in , , /by

Geir Harstad, CEO of Smartfish,

A new clinical study indicates that medical nutrition can improve overall survival in lung cancer patients. 

Oslo Cancer Cluster member Smartfish AS presented the results from a randomized, double-blinded, placebo-controlled trial in the beginning of September. It evaluated one of the company’s medical nutrition products in patients with non-small-cell lung cancer (the most common type of lung cancer) suffering from cachexia.

Cachexia is a complex wasting syndrome, known to have a negative impact on clinical outcomes in patients with cancer and several other chronic diseases.

It is characterised by an ongoing loss of muscle and weight, that eventually can kill the patient.

The results show that the nutrition has a favorable safety profile and indicate a number of positive effects on clinical outcome, for instance that the patients who received the nutrition experienced numerically fewer adverse events from their chemotherapy treatments than the comparator group.

The clinical study

In the pilot study, lung cancer patients who received the nutrition while being pre-cachectic had a statistically significant higher survival after 12 months from baseline compared to the comparator group. 56 patients from 16 clinical sites in Sweden, Italy, Slovakia and Croatia were randomized to receive either Smartfish’s medical nutrition product or a milk-based isocaloric drink.

“This study shows the potential of Remune as an important enhancer of standard cancer care and clinical data like this helps to build awareness of what targeted medical nutrition can do for patients. We are encouraged to continue our research and development to ensure that the best possible nutrition is delivered to the patients who need it.” Geir Harstad, CEO of Smartfish

The medical nutrition product that was tested is called Remune, and is a juice-based drink produced with a proprietary emulsion technology containing unique high levels of Omega 3 fatty acids, vitamin D and whey protein.

The study was recently published online in the journal Nutrition and Cancer and can be read following this link: “Safety and Tolerability of Targeted Medical Nutrition for Cachexia in Non-Small-Cell Lung Cancer: A Randomized, Double-Blind, Controlled Pilot Trial” .

About Smartfish AS

Smartfish AS is active in the research, development, production and marketing of advanced and clinically documented nutritional drinks within medical nutrition and sports nutrition. All Smartfish products are produced on its proprietary juice-based emulsion technology platform with the marine DHA and EPA fatty acids as important ingredients. Smartfish has a number of ongoing clinical development projects and studies in close collaboration with researchers and institutions both in Norway and internationally. The company was founded in 2001 and is located in Oslo, Norway and Lund, Sweden. Smartfish’s main shareholders are Investinor (Norway) and Industrifonden (Sweden). For more information, visit SmartFish official website.

For more information about the study and the company, please contact Jens Nordahl, VP Sales & Marketing, tel +47 996 299 99.

The company’s press release can be read as a PDF in this link.

 

Sign up to OCC monthly newsletter

The panelists during our breakfast meeting about precision medicine in Arendal: (from left to right) Audun Hågå, Director (Norwegian Medicines Agency), Per Morten Sandset, vice principal for Innovation (University of Oslo), Tuva Moflag (Ap), Marianne Synnes (H), Geir Jørgen Bekkevold (KrF).

Together for precision medicine

/in , , , , , /by

Debate from Arendalsuka

During Arendalsuka 2019, we arranged a breakfast meeting on the development of cancer treatments of the future, together with LMI and Kreftforeningen.

Arendalsuka has become an important arena for those who want to improve aspects of Norwegian society. We were there this year to meet key players to accelerate the development of cancer treatments.

Our main event of the week was a collaboration with Legemiddelindustrien (LMI) and The Norwegian Cancer Society (Kreftforeningen). We wanted to highlight the cancer treatments of the future and whether Norway is equipped to keep up with the rapid developments in precision medicine. (Read a summary of the event in Norwegian on LMI’s website)

First speaker, Line Walen (LMI), presented the problems with the traditional system for approving new treatments in face of precision medicine.

The second presenter, Kjetil Taskén (Oslo University Hospital), introduced their new plan at Oslo University Hospital to implement precision medicine.

Then, Steinar Aamdal (University of Oslo) talked about what we can learn from Denmark when implementing precision medicine.

Lastly, Ole Aleksander Opdalshei (Norwegian Cancer Society) highlighted a new proposal for legislation from the government.

The exciting program was followed by a lively discussion between both politicians and cancer experts.

There was general agreement in the panel that developments are not happening fast enough and that the Norwegian health infrastructure and system for approving new treatments is not prepared to handle precision medicine, even though cancer patients need it immediately.

The panelists proposed some possible solutions:

  • Better collaboration and public-private partnerships between the health industry and the public health sector.
  • More resources to improve the infrastructure for clinical trials, with both staff, equipment and financial incentives.
  • Better use of the Norwegian health data registries.

After the debate, we interviewed a few of the participants and attendees. We asked: which concrete measures are needed for Norway to get going with precision medicine?

Watch the six-minute video below (in Norwegian) to find out what they said. (Turn up the sound)


 

Did you miss the meeting? View the whole video below on YouTube (in Norwegian).

 

Full list of participants:

  • Wenche Gerhardsen, Head of Communications, Oslo Cancer Cluster (Moderator)
  • Line Walen, Senior Adviser, LMI
  • Kjetil Taskén, director Institute for Cancer Research, Oslo University Hospital
  • Steinar Aamdal, professor emeritus, University of Oslo
  • Ole Aleksander Opdalshei, assisting general secretary, The Norwegian Cancer Society
  • Marianne Synnes (H), politician
  • Geir Jørgen Bekkevold (KrF), politician
  • Tuva Moflag (Ap), politician
  • Per Morten Sandset, vice principal for Innovation, University of Oslo
  • Audun Hågå, Director Norwegian Medicines Agency

 

Thank you to all participants and attendees!

The next event in this meeting series will take place in Oslo in the beginning of next year. More information will be posted closer to the event.

We hope to see you again!

 

Organisers:

 

 

 

 

 

Sponsors:

 

 

 

 

 

Sune Justesen and Stephan Thorgrimsen from Immunitrack are pleased to receive the Eurostars funding to continue to develop the company's prediction tools. Photo: Immunitrack

New tool to improve cancer vaccines receives funding

/in , , , , , /by

Sune Justesen and Stephan Thorgrimsen from Immunitrack

Oslo Cancer Cluster member Immunitrack has been awarded a grant from Eurostars to develop their prediction tool for cancer vaccines.

Immunitrack is a biotech company that develops software, which predicts immune responses and assesses new cancer vaccines.

Developing a new vaccine can be a lengthy and expensive process, with a high risk of failure. One key to success is being able to predict how the patient’s immune system will react, so drug developers can bring forth therapies that mobilize the immune system to fight the disease. Immunitrack’s tools can help developers predict the impact of a new drug on the patient’s immune system, before entering clinical trials.

Eurostars supports international innovative projects and is co-funded by Eureka member countries and the European Union Horizon 2020 framework programme. The funding will be used by Immunitrack over a 24-month period for the ImmuScreen Project, to develop a new prediction tool. It will both improve how cancer vaccines work and how to track patients’ immune responses.

“This Eurostar project will give additional momentum to the ongoing development of a best in class neo-epitope prediction tool, PrDx TM, by Immunitrack,” says Sune Justesen, CSO at Immunitrack.

Immunitrack will receive a total of approximately €750 000 from Eurostars, together with the Centre for Cancer Immune Therapy (CCIT), based in Herley, Denmark. CCIT aims to bridge the gap between research discovery and clinical implementation of treatments in the field of cancer immunotherapy.

“The collaboration with the Danish Cancer Center for Immune Therapy, is certainly an important step in validating and implementing PrDx, in the immune therapy treatment of cancer patients,” says Sune Justesen, CSO at Immunitrack.

Immunitrack will handle the software development, while CCIT performs the in vitro validation. The clinical validation will be carried out in melanoma patients. The results will help to characterize immune responses and help to understand why some tumours are immune to novel cancer vaccines.

 

Sign up to OCC monthly newsletter